Impending new guidelines on prescribing biologics advise German doctors to consider the economic case for prescribing a biosimilar instead of the reference product. The guidelines are a first step towards increasing usage of biosimilars in a bid to save costs.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?